PT  - JOURNAL ARTICLE
AU  - Wiseman, David M.
AU  - Kory, Pierre
AU  - Saidi, Samir A
AU  - Mazzucco, Dan
TI  - Effective post-exposure prophylaxis of Covid-19 associated with hydroxychloroquine: Prospective dataset re-analysis incorporating novel, missing data
AID  - 10.1101/2020.11.29.20235218
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.11.29.20235218
4099  - http://medrxiv.org/content/early/2021/07/05/2020.11.29.20235218.short
4100  - http://medrxiv.org/content/early/2021/07/05/2020.11.29.20235218.full
AB  - BACKGROUND A key trial (NCT04308668) of post-exposure prophylaxis found hydroxychloroquine-associated (HCQ) reductions of Covid-19 by 17% overall and 31% to 49% in subgroups. To understand these trends, we re-analyzed the dataset.METHODS Our protocol conformed to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT). We compared the incidence of Covid-19 after HCQ or placebo, stratifying by intervention lag, age, and gender.RESULTS Newly requested data missing from the dataset revealed that 52% and 19% of subjects received medication 1-2 days after intended and assumed overnight delivery or four-day intervention lag respectively. After re-analysis, we found reduced HCQ-associated incidence of Covid-19 with Early (up to 3 days post-exposure) (RR 0.58, 95%CI 0.35 - 0.97; p=0.044; NNT 14.5) but not Late (RR 1.22, 95%CI 0.72 - 2.04) prophylaxis.We found a significant HCQ-associated Covid-19 reduction in subjects 18 to 45 years old with Early (RR 0.54, 95%CI 0.29-0.97; p=0.0448, NNT 11.5) but not Late (RR 1.02, 95%CI 0.55-1.89) prophylaxis, attenuated in older subjects (RR 0.75, 95%CI 0-27-2.05) and by co-morbidities. Although, we did not detect effects of gender, folate, zinc, or ascorbate, confounding effects cannot be excluded.CONCLUSIONS Using novel data and prospective re-analysis, hydroxychloroquine, in an age-dependent manner, was associated with reduced Covid-19 compatible illness when supplied for post-exposure prophylaxis between 1 and 3 days after high- or moderate-risk exposure, at higher loading and maintenance doses than in similar studies. The original study conclusions are controverted, and our finding warrants prospective confirmation.Protocol registered at Open Science Framework: osf.io/fqtnw (last revised September 27, 2020,HighlightsMissing data integrated with dataset re-analysis reversed findings of original studyHydroxychloroquine associated reduction (42%) of Covid-19 compatible illness foundEffect in Post-exposure Prophylaxis when received 1-3 days after exposureRisk Ratio 0.58 (95% CI 0.35-0.97, p=0.044, NNT14.5)Findings controvert the conclusions of original studyCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04308668Clinical Protocols https://osf.io/hyp8k/ https://www.medrxiv.org/content/10.1101/2020.08.19.20178376v2 Funding StatementThere is no external support for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval was required for this work. This is a re-analysis of a de-identified, publicly released dataset obtained from an IRB-supervised study. Additional requested data were de-identified data and provided after we had been advised that the Privacy Officer of the University of Minnesota would be consulted to ensure regulatory compliance.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMicrosoft Excel files will be available on reasonable request up to one year after publication to qualified investigators subject to an agreed upon data sharing agreement. The source dataset is available from the original authors.HCQHydroxychloroquine (and its salts)HCWHealth Care WorkerITTIntent to TreatmITTModified Intent to TreatNNTNumber Needed to TreatPCRPolymerase Chain ReactionPEPPost-Exposure ProphylaxisPETPost Exposure TreatmentPPEPersonal Protective EquipmentPrEPPre-Exposure prophylaxisRCTRandomized Clinical Trial